Huateng Pharmaceutical, a global supplier of pharmaceutical intermediates, offers 3,6-Difluoro-2-Pyrazinecarbonitrile (CAS NO. 356783-28-3), which is a useful fluorinated building block and favipiravir intermediates.
Favipiravir, also known as T-705 or Avigan, is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.
